• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Why Agilon Health Stock Is Up 18.2% And What's Next

    Simply Wall St·11/06/2026 05:22:41
    Listen to the news
    • Agilon Health reported Q3 2026 revenue of US$1.52b and net income of US$34.91m, with earnings per share turning positive versus a loss a year earlier.
    • The business paired this profitability shift with higher full year revenue guidance of US$5.87b to US$5.89b. Management attributed the updated outlook to operational execution as membership and medical cost programs run through the model.
    • We will now look at how agilon health's raised full year revenue guidance could shape the broader investment narrative around its model.

    Compare agilon health's profitability turn with a curated set of peers by scanning 42 high quality undervalued stocks, which also pair solid fundamentals with potential mispricing.

    agilon health Investment Narrative Recap

    For agilon health, the big picture you need to believe in is that a full risk, value based primary care model for seniors can convert clinical programs and data capabilities into consistent earnings. The Q3 move to net income and positive EPS is an early proof point, but the key short term catalyst is still execution on medical cost trends across existing Medicare Advantage and ACO partnerships.

    The biggest risk remains membership pressure after prior market exits and tighter contracts. If covered lives stagnate or fall, operating leverage could stall even with better per member economics. The latest results help reduce near term uncertainty around profitability, but they do not remove the volume and cash burn questions raised over the past year.

    The raised full year revenue guidance to US$5.87b to US$5.89b is the clearest announcement to focus on alongside Q3 earnings. Guidance now sits slightly above earlier expectations, which ties directly into the main catalyst for agilon health: improving the quality and predictability of its per member revenue streams while it tightens underwriting discipline.

    You can read this change as management leaning into the current operating run rate as membership, data driven risk adjustment and clinical pathways run through the model. The risk side is just as important. If revenue progresses toward the guided range without a similar improvement in cash generation, or if membership softness returns, then concerns about the durability of this value based care model could resurface quickly.

    agilon health’s current analyst narrative points to revenues of US$7.4b and earnings of US$77.9m by 2029, built on an assumed 7.6% yearly increase in revenue and an earnings swing of roughly US$329m from a loss of US$251.2m today to the projected profit level.

    Uncover why agilon health's fair value is essentially in line with its current price.

    NYSE:AGL 1-Year Stock Price Chart
    NYSE:AGL 1-Year Stock Price Chart

    Exploring Other Perspectives

    One bullish twist on agilon health focuses on ACO REACH and Senior Health Connect as a separate growth engine, less tied to Medicare Advantage membership swings that worried the baseline narrative. The most optimistic analysts were already penciling in US$7.9b of revenue and US$320.2m of earnings by 2029. After this earnings surprise and guidance raise, those pre news forecasts may be revisited. Treat them as one possible path and explore how different they are from more cautious views.

    Explore 2 other agilon health fair value estimates, including one that suggests as much as 362% upside from the current price!

    Form Your Own Verdict

    Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

    Looking For More agilon health Style Investment Ideas?

    If agilon health has sharpened your focus on business models and fundamentals, broaden your watchlist with a few targeted screens that surface stocks based on the traits you care about most.